Rocket Pharmaceuticals, Inc. (RCKT)
- Sector
- Biotechnology
- Last price
- $2.58
- As of
Kresmion compiles this page from RCKT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ROCKET PHARMACEUTICALS, INC. (RCKT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full RCKT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RCKT on one page. Preview it with sample data, then open it live with a free account.
Preview the RCKT dossierActive events for RCKT
- high13F: funds reduced
3 tracked funds reduced RCKT this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +149% to RCKT (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +127% to RCKT (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 56% of RCKT (2026Q2)
- high13F: large reduction
TWO SIGMA INVESTMENTS, LP cut 71% of RCKT (2026Q2)
FREE, NO ACCOUNT
Every event on RCKT, as it fires
You are seeing 5 of 11 events recorded on RCKT since 2026-06-04.
The five above landed across 2 days. The other 6 were recorded on 3 other days. 7 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RCKT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 77313F106 · 2026Q2 | $13.7M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 77313F106 · 2026Q2 | $3.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 77313F106 · 2026Q2 | $2.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 77313F106 · 2026Q2 | $2.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 77313F106 · 2026Q2 | $1.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 77313F106 · 2026Q2 | $243K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RCKT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
RCKT against its peers
RCKT's return on equity of -80.5% ranks in the 36th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RCKT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 10.6M USD | 10 | 14 |
| Operating margin | n/a | -340.4% | n/a | 13 |
| Net margin | n/a | -369.1% | n/a | 14 |
| Return on equity | -80.5% | -38.2% | 36 | 20 |
Peers (22): QTTB, ABEO, OCGN, FATE, LCTX, CABA, BCYC, NWBO, SABS, LRMR, VNDA, IMRX, ACIU, IPSC, GLSI, PALI, LYEL, IFRX, LXEO, SLGL, ARCT, IKT. Left out: VCRE (no annual filing), CUVL (no annual filing), VOGX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RCKT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RCKT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RCKT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.